| Year |
Citation |
Score |
| 2022 |
Woodward A, Faria GNF, Harrison RG. Annexin A5 as a targeting agent for cancer treatment. Cancer Letters. 547: 215857. PMID 35940392 DOI: 10.1016/j.canlet.2022.215857 |
0.389 |
|
| 2021 |
McKernan P, Virani NA, Faria GNF, Karch CG, Prada Silvy R, Resasco DE, Thompson LF, Harrison RG. Targeted Single-Walled Carbon Nanotubes for Photothermal Therapy Combined with Immune Checkpoint Inhibition for the Treatment of Metastatic Breast Cancer. Nanoscale Research Letters. 16: 9. PMID 33411055 DOI: 10.1186/s11671-020-03459-x |
0.391 |
|
| 2018 |
Virani NA, Thavathiru E, McKernan P, Moore K, Benbrook DM, Harrison RG. Anti-CD73 and Anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Letters. PMID 29574275 DOI: 10.1016/J.Canlet.2018.03.027 |
0.372 |
|
| 2017 |
Krais JJ, Virani N, McKernan PH, Nguyen Q, Fung KM, Sikavitsas VI, Kurkjian CD, Harrison RG. Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide. Molecular Cancer Therapeutics. PMID 28522586 DOI: 10.1158/1535-7163.Mct-16-0263 |
0.36 |
|
| 2016 |
Guillen KP, Ruben EA, Virani N, Harrison RG. Annexin-directed β-glucuronidase for the targeted treatment of solid tumors. Protein Engineering, Design & Selection : Peds. PMID 27986920 DOI: 10.1093/protein/gzw063 |
0.44 |
|
| 2016 |
Virani N, Slaton J, Davis C, Hurst R, Hauser P, Harrison R. MP61-08 PHOTOTHERMAL ABLATION OF BLADDER CANCER USING PHOSPHATIDYLSERINE TARGETED CARBON NANOTUBES Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.882 |
0.503 |
|
| 2015 |
Guillen KP, Restuccia A, Kurkjian C, Harrison RG. Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer. Pancreas. 44: 945-52. PMID 25899647 DOI: 10.1097/MPA.0000000000000343 |
0.363 |
|
| 2014 |
Guillen KP, Kurkjian C, Harrison RG. Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase. Journal of Biomedical Science. 21: 65. PMID 25047949 DOI: 10.1186/s12929-014-0065-3 |
0.424 |
|
| 2013 |
Krais JJ, De Crescenzo O, Harrison RG. Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy. Plos One. 8: e76403. PMID 24098491 DOI: 10.1371/journal.pone.0076403 |
0.532 |
|
| 2013 |
Van Rite BD, Krais JJ, Cherry M, Sikavitsas VI, Kurkjian C, Harrison RG. Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature. Cancer Investigation. 31: 505-10. PMID 24083814 DOI: 10.3109/07357907.2013.840383 |
0.769 |
|
| 2013 |
Neves LF, Krais JJ, Van Rite BD, Ramesh R, Resasco DE, Harrison RG. Targeting single-walled carbon nanotubes for the treatment of breast cancer using photothermal therapy. Nanotechnology. 24: 375104. PMID 23975064 DOI: 10.1088/0957-4484/24/37/375104 |
0.763 |
|
| 2011 |
Prickett WM, Van Rite BD, Resasco DE, Harrison RG. Vascular targeted single-walled carbon nanotubes for near-infrared light therapy of cancer. Nanotechnology. 22: 455101. PMID 21993223 DOI: 10.1088/0957-4484/22/45/455101 |
0.793 |
|
| 2011 |
Van Rite BD, Harrison RG. Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine. Cancer Letters. 307: 53-61. PMID 21546157 DOI: 10.1016/j.canlet.2011.03.016 |
0.795 |
|
| 2011 |
Van Rite BD, Lazrak YA, Pagnon ML, Palwai NR, Neves LF, McFetridge PS, Harrison RG. Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature. Cancer Letters. 301: 177-84. PMID 21194833 DOI: 10.1016/J.Canlet.2010.11.013 |
0.729 |
|
| 2010 |
Neves LF, Tsai TW, Palwai NR, Martyn DE, Tan Y, Schmidtke DW, Resasco DE, Harrison RG. Non-covalent attachment of proteins to single-walled carbon nanotubes. Methods in Molecular Biology (Clifton, N.J.). 625: 3-8. PMID 20422376 DOI: 10.1007/978-1-60761-579-8_1 |
0.741 |
|
| 2009 |
Palwai NR, Zang XP, Harrison RG, Benbrook D, Pento JT. Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor. Pharmacology. 84: 271-5. PMID 19797936 DOI: 10.1159/000242997 |
0.797 |
|
| 2009 |
Tsai TW, Heckert G, Neves LF, Tan Y, Kao DY, Harrison RG, Resasco DE, Schmidtke DW. Adsorption of glucose oxidase onto single-walled carbon nanotubes and its application in layer-by-layer biosensors. Analytical Chemistry. 81: 7917-25. PMID 19788314 DOI: 10.1021/Ac900650R |
0.608 |
|
| 2007 |
Palwai NR, Zang XP, Harrison RG, Pento JT. Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells. Anticancer Research. 27: 3435-9. PMID 17970092 |
0.803 |
|
| 2007 |
Palwai NR, Martyn DE, Neves LFF, Tan Y, Resasco DE, Harrison RG. Retention of biological activity and near-infrared absorbance upon adsorption of horseradish peroxidase on single-walled carbon nanotubes Nanotechnology. 18. DOI: 10.1088/0957-4484/18/23/235601 |
0.751 |
|
| 2006 |
Zang XP, Palwai NR, Lerner MR, Brackett DJ, Pento JT, Harrison RG. Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration. Anticancer Research. 26: 1745-51. PMID 16827102 |
0.808 |
|
| 2006 |
Zang X, Palwai NR, Pento JT, Harrison RG. Internalizing Versus Non-internalizing Receptors for Targeting L-Methioninase to Cancer Cells American Journal of Pharmacology and Toxicology. 1: 60-64. DOI: 10.3844/Ajptsp.2006.60.64 |
0.798 |
|
| 2003 |
Peron K, Jones TN, Gauthier SA, Nguyen TN, Zang XP, Barriere M, Prévéraud D, Soliman CE, Harrison RG, Pento JT. Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation. Cancer Chemotherapy and Pharmacology. 52: 270-6. PMID 12827296 DOI: 10.1007/s00280-003-0666-0 |
0.5 |
|
| 2003 |
Davis GD, Harrison RG. Discovery of new fusion protein systems designed to enhance solubility in E. coli. Methods in Molecular Biology (Clifton, N.J.). 205: 141-54. PMID 12491884 |
0.666 |
|
| Show low-probability matches. |